# Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct01045304/  
OnCo record `nct01045304` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Iniparib, Gemcitabine and Carboplatin in Breast cancer, run by Sanofi, completed.

## Summary

Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer is a phase 2 interventional study registered as NCT01045304 by Sanofi, with 163 participants recorded, started 2010-02 and reaching its primary completion in 2011-03. Interventions recorded: Iniparib, Gemcitabine, Carboplatin. Conditions recorded: Breast Cancer, Metastatic.

Linked to the drug Iniparib because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01045304
- Phase: 2
- Setting: Multicenter, Randomized, Open Label Study Evaluating a Poly(ADP-ribose) Polymerase-1(PARP-1) Inhibitor, SAR240550 (BSI-201), Administered Twice Weekly or Weekly, in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer (mTNBC)
- Sponsor: Sanofi
- Enrolled: 163

## Sources

- ClinicalTrials.gov NCT01045304: https://clinicaltrials.gov/study/NCT01045304

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Iniparib](https://onco.cc/drugs/iniparib/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct01045304.json